SHSana Hatoum

Sana Hatoum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sana Hatoum has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Polycystic ovary syndrome research in sub-Saharan Africa: a systematic review on current status and future directions

    by Sana Hatoum, Mina Amiri, Christian Chigozie Makwe, Joseph Ayodeji Olamijulo, Ricardo Azziz

  • The role of omental sampling in high-grade non-endometrioid endometrial carcinomas

    by Guido M. Rey Valzacchi, Michael W. Burczynski, Ashley N. Hamati, Sana Hatoum, Evan S. Smith, Sarah H. Kim, Jacqueline Feinberg, Vicky Makker, Sarah Chiang, Luisa Ricaurte Archila, et al.

  • Open Access

    Prognostic comparison of the FIGO 2009 and 2023 endometrial cancer staging systems: a large, single-institution retrospective cohort study

    by Tiffany Y. Sia, Qin Zhou, Sean Devlin, Alexia Iasonos, Sana Hatoum, Karen Haney, Sally Kraiem, Christian Dagher, Rofieda Alwaqfi, Eric Rios Doria, et al.


  • Population-Based vs Health System and Insurer Records: Significant Underdiagnosis of PCOS

    by Sana Hatoum, Mina Amiri, Dawnkimberly Hopkins, Richard P Buyalos, Fernando Bril, Ricardo Azziz

    Context: Polycystic ovary syndrome (PCOS) is one of the most prevalent cardio-metabolic disorders in women. However, PCOS diagnosis is often missed or delayed, which may have serious physical and mental health consequences. The extent of underdiagnosis remains unknown. Objective: This work aimed to estimate the extent to which PCOS is underdiagnosed. Methods: We systematically searched PubMed and Embase through July 2023 for studies reporting PCOS prevalence in the general population and the Health System or Insurer Records (HSIR). Results: We identified 6583 records, of which we included 7 population-based studies and 11 HSIR-based studies from the same populations in 3 countries. In the United States, population-based studies reported a PCOS prevalence between 4% and 19.6%, while HSIR-based studies reported 0.2% to 5.2%. In the United Kingdom, an HSIR-based study reported a PCOS prevalence of 1.34%, compared to around 8% prevalence in the population. In South Korea, 2 population-based studies reported a PCOS prevalence of 4.9% and 7%, compared to 0.12% to 0.33% in one HSIR, and 4.3% in another. When data were available, PCOS detection in HSIR appeared to improve over time, although it was still far from reflecting the actual prevalence in the population. Conclusion: Our data revealed a substantially lower rate of PCOS in HSIR relative to population-based studies in the United States, the United Kingdom, and South Korea, likely indicating that PCOS is underdiagnosed and/or underreported. Overall, these findings highlight the critical need to improve the awareness of health care practitioners and payers, and likely the public at large, regarding PCOS.


  • Effect of substantial lymphovascular space invasion on location of first disease recurrence in surgical stage I endometrioid endometrial adenocarcinoma

    by Christian Dagher, Pernille Bjerre Trent, Rofieda Alwaqfi, Ben Davidson, Lora H. Ellenson, Qin Zhou, Alexia Iasonos, Jennifer J. Mueller, Kaled Alektiar, Vicky Makker, et al.


  • Top Cited Papers

    The Influence of Study Quality, Age, and Geographic Factors on PCOS Prevalence—A Systematic Review and Meta-analysis

    by Mina Amiri, Sana Hatoum, Richard P Buyalos, Ali Sheidaei, Ricardo Azziz

    Background: Polycystic ovary syndrome (PCOS) is a highly prevalent disorder with substantial burden, yet global epidemiological data remains limited. Objectives: To estimate the PCOS prevalence globally. Materials and Methods: We systematically searched PubMed and Embase for PCOS studies in unselected populations through February 2024. Results: Our study included 88 studies (n = 561 287 women) from 7144 records. The highest PCOS prevalence was identified by the Rotterdam criteria, followed by the Androgen Excess and PCOS Society (AE-PCOS) and the National Institutes of Health (NIH). High-quality studies, as assessed using our newly developed PCOS Epidemiology and Phenotype (PEP) tool, indicated prevalences of 10.89%, 10.61%, and 6.63% using Rotterdam, AE-PCOS, and NIH, respectively. Considering only high-quality studies revealed no significant regional disparities using either NIH [ranging from 5.72% in the Eastern Mediterranean Region (EMR) to 6.90% in the Western Pacific Region (WPR)] or Rotterdam (ranging from 11.15% in South-East Asia to 9.12% in EMR). For AE-PCOS, sufficient data was available only for the WPR region (6.9%). No studies were available in the African Region. A higher PCOS prevalence was observed in adults than adolescents using NIH (8.52% vs 4.44%; P = .01), although the difference diminished when considering only high-quality studies (7.25% vs 4.44%; P = .053). Limited data restricted age-group comparisons using Rotterdam and AE-PCOS. Conclusion: This systematic review and meta-analysis reveals a trend toward regional variations and age differences across diagnostic criteria. The study results suggest considering study quality using instruments tailored for epidemiological studies in PCOS, such as the PEP tool, when carrying out these types of meta-analyses.


  • Open Access

    Endocrine Disruptors in Pregnancy: Effects on Mothers and Fetuses—A Review

    by Rima Hajjar, Sana Hatoum, Serge Mattar, Gaby Moawad, Jean Marc Ayoubi, Anis Feki, Labib Ghulmiyyah

    Background/Objectives: Endocrine disruptors are ubiquitous agents in the environment and are present in everyday consumer products. These agents can interfere with the endocrine system, and subsequently the reproductive system, especially in pregnancy. An increasing number of studies have been conducted to discover and describe the health effects of these agents on humans, including pregnant women, their fetuses, and the placenta. This review discusses prenatal exposure to various endocrine disruptors, focusing on bisphenols, phthalates, organophosphates, and perfluoroalkyl substances, and their effects on pregnancy and fetal development. Methods: We reviewed the literature via the PubMed and EBSCO databases and included the most relevant studies. Results: Our findings revealed that several negative health outcomes were linked to endocrine disruptors. However, despite the seriousness of this topic and the abundance of research on these agents, it remains challenging to draw strong conclusions about their effects from the available studies. This does not allow for strong, universal guidelines and might result in poor patient counseling and heterogeneous approaches to regulating endocrine disruptors. Conclusions: The seriousness of this matter calls for urgent efforts, and more studies are needed in this realm, to protect pregnant patients, and ultimately, in the long term, society.


  • Open Access

    Endocrine Disruptors in Pregnancy: Effect on Mother and Fetus - A Review

    by Rima Hajjar, Sana Hatoum, Serge Mattar, Gaby Moawad, Jean Marc Ayoubi, Anis Feki, Labib Ghulmiyyah

    Background/Objectives: Endocrine disruptors are ubiquitous agents in the environment and are present in everyday consumer products. These agents can interfere with the endocrine system, and subsequently the reproductive system, especially in pregnancy. Increasing research has been conducted to discover and describe the health effects of these agents on humans, including pregnant women, their fetuses, and the placenta. This review discusses prenatal exposure to various endocrine disruptors focusing on Bisphenols, Phthalates, Organophosphates, and Perfluoroalkyl substances, and their effects on pregnancy and fetal development. Methods: We reviewed the literature via PubMed and EBSCO databases and included the most relevant studies. Results: Our findings reveal that several negative health outcomes were linked to endocrine disruptors. However, despite the seriousness of this topic and the abundance of research on these agents, it remains challenging to draw strong conclusions about their effects from the available studies. This does not allow for strong, universal guidelines and might result in poor patient counseling and heterogeneous approaches to regulating endocrine disruptors. Conclusion: The urgency of the matter calls for urgent efforts, as more studies are needed in this realm, to protect pregnant patients ultimately and in the long term, society.


  • The Association Between Obesity and Polycystic Ovary Syndrome: An Epidemiologic Study of Observational Data

    by Mina Amiri, Sana Hatoum, Dawnkimberly Hopkins, Richard P Buyalos, Uche Ezeh, Lauren A Pace, Fernando Bril, Ali Sheidaei, Ricardo Azziz

    Background: Polycystic ovary syndrome (PCOS) is a common female cardiometabolic-reproductive disorder. It is unclear whether the global obesity epidemic is impacting the high PCOS prevalence. Objective: To determine the association between the prevalence of PCOS and obesity. Materials and methods: A systematic review was conducted to identify population studies on PCOS prevalence globally through July 2023. Linear regression and random-effect models were applied to examine the association of mean body mass index (BMI) or obesity prevalence with the prevalence of PCOS diagnosed by 1990 National Institutes of Health (NIH), 2003 Rotterdam (Rotterdam), and 2006 Androgen Excess-PCOS (AE-PCOS) criteria. Subgroup analyses were also conducted for recruitment methods and study quality. Results: Fifty-eight studies with 85 956 adults from 24 countries were included. Considering all available data, a borderline association was observed between PCOS and obesity prevalence when using the AE-PCOS but not the NIH or Rotterdam criteria. Alternatively, subgroup analysis of studies with better recruitment methods demonstrated a significant positive association of population mean BMI or obesity prevalence with PCOS prevalence when using the Rotterdam or AE-PCOS criteria, while using only high-quality studies revealed an association using NIH as well as Rotterdam and AE-PCOS criteria. Overall, we observed that a 1% increase in obesity prevalence resulted in an approximately 0.4% increase in PCOS prevalence by the Rotterdam criteria. Conclusion: The prevalences of PCOS and obesity appear to be modestly associated, although our data cannot establish causality. This study also emphasizes the need to undertake only high-quality studies in assessing PCOS epidemiology


  • Open Access

    Sclerosing Stromal Tumor of the Ovary Presenting as Meigs Syndrome During Childhood

    by Sana Hatoum, Pascal Jarjoura, Charbel Saade, Lena Naffaa

    Meigs syndrome is a rare disorder characterized by a triad of benign ovarian tumor, ascites, and pleural effusion. Despite its benign nature, its presentation can be similar to metastatic malignancy, making preoperative diagnosis often challenging. The differential diagnosis includes serious and even life-threatening conditions. Meigs syndrome is most common in postmenopausal women and is extremely rare in children. It is often undiagnosed until an invasive surgery is performed. The fact that surgery includes a unilateral salpingo-oophorectomy in females of reproductive age raises concerns for future fertility and other risks associated with this intervention. Familiarity of radiologists and pediatric surgeons with clinical and imaging findings is beneficial to improve preoperative planning, thereby minimizing invasive surgery and preserving ovarian tissue.